CN1301728C - Chinese medicine compound preparation for treating osteoarthropathy and its preparation method - Google Patents
Chinese medicine compound preparation for treating osteoarthropathy and its preparation method Download PDFInfo
- Publication number
- CN1301728C CN1301728C CNB2005100246572A CN200510024657A CN1301728C CN 1301728 C CN1301728 C CN 1301728C CN B2005100246572 A CNB2005100246572 A CN B2005100246572A CN 200510024657 A CN200510024657 A CN 200510024657A CN 1301728 C CN1301728 C CN 1301728C
- Authority
- CN
- China
- Prior art keywords
- group
- radix
- preparation
- compound preparation
- scolopendra
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention belongs to the field of Chinese medicines, which particularly relates to a compound preparation for treating osteoarthropathy and a preparation method thereof. The compound preparation for treating osteoarthropathy is prepared from Chinese medicinal materials such as white peony root, largeleaf gentian root, oyster shell, liquorice root, scolopendra and scorpion as main medicines and auxiliary materials according to a quantitative proportion. Experiment indicates that a high, medium and low dose of the Chinese medicinal compound preparation of the present invention has the functions of resisting inflammation and alleviating pain. The observation to pathological histomorphology of cartilage verifies that the compound preparation can improve the density and the thickness of cartilage cells to lower integrals of osteoarthropathy, delay cartilage degradation and enhance the SOD content of C57 primary OA blood serum of black rats to lower NO and HA contents. The compound preparation has the function of protection cartilage degradation. The preparation method disclosed by the present invention can reserve effective components in medicinal materials with high efficiency and simplify the preparation technology of Chinese medicinal preparations and is favorable to the operation of mass production.
Description
Technical field
The invention belongs to the field of Chinese medicines, relate to a kind of compound Chinese medicinal preparation for the treatment of osteoarthritis, be specifically related to compound preparation of a kind of treatment osteoarthritis that contains Chinese medicines such as the Radix Paeoniae Alba and preparation method thereof.
Background technology:
Osteoarthritis (Osteoarthritis OA) is one of the interior commonly encountered diseases of global range and frequently-occurring disease, good send out in, elderly population, sickness rate raises with age growth, follow the aging of social population, how preventing and treating OA has better become society and the medical matters circle institutes health care issues of concern jointly.Arthritis is one of clinical modal chronic disease, have the title of " No.1 disabling disease ".Arthritis has 100 polytypes, and wherein modal is two kinds of osteoarthritis and rheumatoid arthritis.According to statistics, there are 3.55 hundred million arthritics in the whole world, and wherein 1.9 hundred million is osteoarthritis.In China, have 50% among the crowd more than 50 years old, have among the over-65s crowd 90% women and 80% male to suffer from osteoarthritis, so it has become one of old people's function invalidity, quality of life main reasons for decrease.For promoting the health of suffering from the patient of muscle and skeletal diseases in the global range,, and obtained the positive support of the WHO and the World Bank in the world about orthopedics expert and the patient initiation " skeleton and articulation health took action in 10 years 2000-2010 " of making joint efforts.The government of 42 countries and regions such as the at present existing U.S., Britain announces approval and supports this action.On October 12nd, 2002, the 3rd international joint buring sun, Chinese Government announces to become a full member of in the enforcement of this plan.
At present, the treatment of osteoarthritis is based on non-operative treatment, and Western medicine is used all kinds of nonsteroidal anti-inflammatory analgetics (NSAIDs) more, and beginning utilization relief of symptoms medicine is a Chondroprotective agents in recent years.The new NSAIDs that the COX-2 selectivity suppresses becomes the popular development field of bio-pharmaceuticals industry.1999, this quasi drugs sales volume was 14.7 hundred million dollars, reached 2,600,000,000 dollars in 2000, increased extremely rapidly, and wherein, 2,200,000,000 dollars of American market sales volumes have increased by 63%.The oral formulations of Chondroprotective agents was taken generally more than three weeks, was also referred to as and acted on the relief of symptoms medicine slowly.Therefore, the world of medicine is being devoted to seek the medicine of better treatment osteoarthritis always, and Chinese medicine had become the focus of research in recent years.Chinese medicine osteopathia with a long history, the principle reasonable formula of pressing treating both the principal and secondary aspects of a disease is sought the breach, is the feasible way that is expected to obtain satisfactory effect.
Summary of the invention
The purpose of this invention is to provide a kind of compound Chinese medicinal preparation for the treatment of osteoarthritis and preparation method thereof.
Though Chinese medicine does not have clear and definite osteoarthritis name of disease, the symptom of relevant this type of disease is described the category of being more common in " numbness ", and the ancient Chinese medicine doctor opinion is controlled this type of disease and had their own characteristics each, and many scholars in recent years use the Chinese medicine osteoarthritis also to obtain corresponding curative effect.The person of modern times is many to be classified as arthromyodynia (rheumatism involving the bone) with osteoarthritis, and this classification is many to be foundation with primary disease pain, handicapped clinical symptoms, " interior warp " " numbness is closed also ... wet three gas of wind and cold are assorted extremely, close and be numbness also " cause symptoms such as pain, action is limited." Huatuo's Zhongzang classic " also points out " rheumatism involving the bone person is that addiction does not save, and hinders in kidney also the kidney qi internal diabetes ... then vital essence day declines ... pathogen is absurd goes into ".Each family report thinks all and primary disease and caused by liver and kidney deficiency, exopathogen invades muscles and bones to cause venation obstructed that exopathogen is detained, and arthromyodynia is to become.
The present invention presses the principle for the treatment of both the principal and secondary aspects of a disease, adopts nourish blood profit muscle, removing obstruction in the collateral to relieve pain scheme, is principal agent with the Chinese crude drug Radix Paeoniae Alba, Radix Gentianae Macrophyllae, Concha Ostreae, Radix Glycyrrhizae, Scolopendra and Scorpio, is equipped with adjuvant, makes the compound Chinese medicinal preparation that the present invention treats osteoarthritis.
Medicine that the present invention adopts shows that through modern pharmacological research wherein: the Radix Paeoniae Alba contains compositions such as white peony root's total glycoside, benzoic acid, tannin, and white peony root's total glycoside has pharmacological actions such as antiinflammatory and immunomodulating, is used for the treatment of arthritis and senile disease clinically, and effect is better.Histopathology is observed and is shown, by the inductive adjuvant arthritis rats of the left back sufficient sole of the foot intradermal injection of Freund's complete adjuvant, after the white peony root's total glycoside treatment, the cellulose of ankle joint oozes out, the hypertrophy of the infiltration of inflammatory cell and synovial membrane all is starkly lower than matched group, and can increases thymic cortex thickness and medullary substance lymphocyte density.White peony root's total glycoside has restitution to the mice delayed hypersensitivity that cyclophosphamide is reduced; The mice delayed hypersensitivity that cyclophosphamide is increased then has inhibitory action simultaneously.Serum glutamic pyruvic transminase raise after white peony root's total glycoside prevention administration can obviously resist D-galactosamine or the hepatic injury of carbon tetrachloride induced mice, sero-abluminous decline and hepatic glycogen content reduce, and morphologic hepatocellular degeneration and necrosis are significantly improved and recover.
Contain gentianin (Gentianine) in the Radix Gentianae Macrophyllae root that is adopted, gentianidine (Gentianidine), gentianal, saccharide and volatile oil.Still contain gentiopicrin in Radix Gentianae Macrophyllae and the radix gentiane dahuvicae root.Radix Gentianae Macrophyllae decoct and ethanol-soluble extractives, heavy dose of to the experimental heating of rat have refrigeration function.The Radix Gentianae Macrophyllae alcohol extract all has in various degree bacteriostasis to staphylococcus aureus, pneumobacillus, Bacillus typhi and dermatophytes.Radix Gentianae Macrophyllae alkaloid first can alleviate rat because of injecting the swollen joint that formaldehyde or Ovum Gallus domesticus album produce, and low dose of have sedation to little from Mus and rat; Radix Gentianae Macrophyllae alkaloid first water and alcohol extract have the effect that reduces animal blood pressure, and certain antianaphylaxis shock and antihistaminic effect are arranged, and capillary percolation is obviously reduced, and rat is had the painful effect in certain town.The rats by intraperitoneal injection gentianin has inhibitory action to rat formaldehyde and Ovum Gallus domesticus album arthroncus.
Contain the Scorpio poison in the Scorpio of being adopted, analgesic activity with rat and conventional heat radiation the getting rid of property method of mice and acetic acid twisting method mensuration scorpion body and scorpion tail shows, no matter the isotonic solution of scorpion body and scorpion tail is irritated stomach or quiet notes, animal body pain, Encelialgia all there is obvious analgesic activity.The centipede dry powder suspension is given the Turnover of Mouse Peritoneal Macrophages phagocytic activity effect that is improved of mouse stomach, high low dose group, and activating macrophage FC receptor is arranged, and reducing the super quick value of mice has the effect that alleviates immune organ weight.
Chinese crude drug involved in the present invention is recorded Chinese medicine by Chinese Pharmacopoeia one one of version in 2000, and meets the pharmacopeia prescription.
Described each the amounts of components proportioning such as following of compound preparation of the present invention is mass/mass percentage ratio,
Radix Paeoniae Alba 20-40%, Radix Gentianae Macrophyllae 10-20%, Concha Ostreae 20-40%, Radix Glycyrrhizae 10-20%, Scolopendra 1-5%, Scorpio 1-5%.
Compound preparation of the present invention prepares by following method and step,
By above-mentioned amount ranges, get the Radix Paeoniae Alba, Radix Gentianae Macrophyllae, Concha Ostreae and Radix Glycyrrhizae respectively, 90 ℃ of extracting in water secondaries, add for the first time 6 times of amounts of water, extracted 30 minutes, and added 4 times of amounts of water for the second time, extracted 30 minutes, filter, merge fried liquid, being evaporated to relative density is 1.20～1.25 (80 ℃) clear paste, (60 ℃ of drying under reduced pressure, 0.08MPa), be ground into fine powder (crossing 40 orders); Other gets Scolopendra and Scorpio, pulverizes 40 orders,
60Co-gamma-ray irradiation sterilization (8KGy) with the dry extract mixing, incapsulates promptly and gets (0.35g/ grain).
The gained capsule, through assay and discriminating and quality examinations such as disintegration, moisture, the result shows, meets the every regulation of Chinese Pharmacopoeia version in 2000 to the tablet routine examination.
Compound preparation of the present invention is its preparation technology determine according to following optimization:
1, the extraction process of the Radix Paeoniae Alba, Radix Gentianae Macrophyllae, Concha Ostreae and liquorice beverage
1) extraction time determines
Sample preparation
Extract 2 sample preparations: take by weighing compound preparation one card amount of the present invention (40 gram), add 6 times of water gagings, soaked 30 minutes, heated and boiled 45 hours adds 4 times of water gagings again, heated and boiled 30 hours, and merge extractive liquid, is evaporated to about 25ml.
Extract 3 sample preparations: take by weighing compound preparation one card amount of the present invention (40 gram), add 6 times of water gagings, soaked heated and boiled 45 hours 30 minutes, add 4 times of water gagings again, heated and boiled 30 hours adds 4 times of water gagings again, heated and boiled 30 hours, merge extractive liquid, is evaporated to about 25ml.
2) assay
Measure the extract of said extracted the 2nd time and 3 times respectively, press content assaying method mensuration peoniflorin and Determination of gentiopicroside wherein, the result shows, extract for 2 times and 3 extraction samples in peoniflorin equal substantially with Determination of gentiopicroside, show that 2 extractions have made the effective ingredient in the compound recipe extract substantially fully.Therefore this compound preparation is selected extraction time for use 2 times.Table 1 is a content of paeoniflorin in the different extraction times.Determination of gentiopicroside in the different extraction times of table 2.
Table 1
| Sample | Content (mg) |
| Extract to extract for 2 times to extract for 2 times and extract 3 times for 3 times | 5.446 6.610 5.104 5.048 |
Table 2
| Sample | Content (mg) |
| Extract to extract for 2 times to extract for 2 times and extract 3 times for 3 times | 13.728 15.498 13.977 14.155 |
2) orthogonal experiment conceptual design
According to The above results, respectively with peoniflorin and gentiopicrin as evaluation index, investigate water temperature raising degree, amount of water and extraction time 3 factors, each factor is got 3 levels, selects for use L9 (34) orthogonal table to test.Table 3 is the factor level calendar.
Table 3
| Level | Factor | |||
| A extraction temperature (℃) | B amount of water (doubly) | C extraction time (min) | The D extraction time | |
| 1 2 3 | 100 90 80 | 8,6 6,4 4,3 | 90 60 30 | 2 2 2 |
Take by weighing medical material by described each amounts of components of compound preparation of the present invention, according to L9 (34) orthogonal table arrangement test, extracting solution filters with four layers of yarn, merges fried liquid, is evaporated to about 25ml.Measure peoniflorin and Determination of gentiopicroside respectively.Table 4 is taken into account interpretation of result for orthogonal experiment plan.
Table 4
| Factor | A | B | C | D | Paeoniflorin content | Gentiopicroside in different morphological | The rate of extract (%) | |
| Tested number | 1 2 3 4 5 6 7 8 9 | 1 1 1 2 2 2 3 3 3 | 1 2 3 1 2 3 1 2 3 | 1 2 3 2 3 1 3 1 2 | 1 2 3 3 1 2 2 3 1 | 4.6899 6.8880 7.3850 6.8087 8.1554 7.8933 7.5954 8.3446 7.9659 | 15.7150 17.3674 16.6081 18.2455 21.1104 20.4005 18.9910 19.5197 18.3089 | 12.44 12.39 11.96 11.86 12.47 12.04 11.56 11.67 10.60 |
| Peoniflorin | I II III R S P | 18.9629 22.8574 23.9059 4.9431 4.5223 --- | 19.0940 23.3880 23.2442 4.2940 3.9648 --- | 20.9277 21.6627 23.1358 2.2080 0.8428 --- | 20.8112 22.3766 22.5384 1.7272 0.6067 --- | G＝50.7036 CT＝G 2/9＝285.6510 SJ＝(K12+K22+132)/3-CT | ||
| Gentiopicrin | I II III R S P | 49.6905 59.7564 56.8196 10.0659 17.8634 --- | 52.9516 57.9975 55.3176 5.0459 4.2491 --- | 55.6352 53.9218 56.7096 2.7878 1.3180 --- | 55.1344 56.7590 54.3732 2.3857 0.9900 --- | G＝72.8212 CT＝G 2/9＝589.2136 SJ＝(K12+K22+K32)/3-CT | ||
| The rate of extract | I II III R S P | 36.7844 36.3644 33.8244 2.9601 1.7100 ＜0.05 | 35.8544 36.5198 34.5990 1.9208 0.6342 --- | 36.1458 34.8469 35.9805 1.2989 0.3333 --- | 35.5099 35.9845 35.4788 0.5057 0.0535 --- | G＝167.5120 CT＝G 2/9＝3117.8078 SJ＝(K12+K22+K32)/3-CT | ||
The above results shows that for peoniflorin, the principal element that influences content is A＞B＞C, and 3 factors are right.Get the best A3B2C3 that is combined as by the intuitive analysis method; For gentiopicrin, the principal element that influences content is A＞B＞C, and 4 factors get the best A2B2C3 that is combined as to Determination of gentiopicroside there are no significant difference (P＞0.05) by the intuitive analysis method; Estimate by yield of extract, the principal element that influences content is A＞B＞C, and wherein factor A is major influence factors (P＜0.05).Get the best A1B2C1 that is combined as by the intuitive analysis method.
Wherein, factor A had both extracted temperature, was the principal element to the rate of extract influence, but not remarkable to the influence of peoniflorin and gentiopicroside in different morphological, wherein 80 ℃ of extractions that help peoniflorin of the 3rd level, 90 ℃ of extractions that help gentiopicrin; Factor B is amount of water both, to three indexs there are no significant the influence, gentiopicrin and content of paeoniflorin then demonstrate second level the best as index, promptly amount of water is 6,4 times; Factor C is extraction time both, to there are no significant the influence of peoniflorin and Determination of gentiopicroside, and all show the 3rd level both extraction time be 30 minutes, the content of index components is the highest, so the inventive method was selected 3 levels for use both 30 minutes.
According to above result of the test, the preliminary technology conclusion of the present invention is that water is carried secondary, 80 ℃ or 90 ℃ of each temperature, and amount of water is 6 times for the first time, 4 times for the second time, extraction time is 30 minutes.
For confirming the stability of this method, according to above result of the test, the present invention is amount of water (6 times, 4 times) fixedly, and extraction time (30min) and extraction time (2 times) are investigated 80 ℃ and 90 ℃ respectively, carries out the repeatability checking.Result's demonstration is extracted as with 90 ℃, and three batches of reproducible results show stable contents.Table 5 is optimization process repeated trials result (n=3).
Table 5
| 90℃ | 80℃ | |||
| Content (mg/g) | Average content (mg/g) | Content (mg/g) | Average content (mg/g) | |
| Peoniflorin gentiopicrin the rate of extract | 8.04 8.21 8.41 19.49 21.06 20.99 0.1108 | 8.22 20.33 | 8.04 8.31 8.19 17.72 18.94 18.80 0.1113 | 8.19 18.49 |
Compound Chinese medicinal preparation of the present invention confirms that through the zoopery result its high, medium and low dosage all has antiinflammatory, analgesic activity.Observation to cartilage pathology tectology; confirm that it can improve chondrocyte density and thickness; thereby reduce the osteoarthritis integration; delay cartilage degeneration; promote the black Mus SOD in serum content of C57 constitutional OA and reduce NO, HA content; cartilage degradation is played a protective role, can be used for the treatment of osteoarthritis.
The specific embodiment
By the further beneficial effect of setting forth compound Chinese medicinal preparation of the present invention of following test example.
The antiinflammatory action of test example 1 compound preparation of the present invention
Experiment material:
1) is subjected to the reagent thing: compound Chinese medicinal preparation of the present invention.
2) animal subject: Kunming kind white mice, body weight 20g ± 0.5g, male and female half and half, the SD rat is provided by Shanghai Univ. of Traditional Chinese Medicine's Experimental Animal Center.
Experimental technique and result:
Mice dimethylbenzene auricle edema method is got 61 of white mice, is divided into 5 groups at random by body weight, and 12 every group, male and female half and half.Test the same day, the normal control group gives the equivalent normal saline, ibuprofen group 157mg/Kg, compound preparation I group 0.2g/Kg of the present invention, compound preparation II group 0.4g/Kg of the present invention, compound preparation III group 0.8g/Kg of the present invention.Each is organized medicine and irritates stomach, and administration capacity 0.2ml/ only.After 1 hour, only be coated with left ear contrast with dimethylbenzene 0.05ml/ to mouse right ear, put to death animal after 15 minutes, ears are downcut with the position homalographic, accurately weigh with diameter 6mm card punch, the difference of left and right sides auricle weight is the swelling degree, calculates and respectively organizes swelling rate and swelling inhibition percentage rate.The result shows that the equal xylol induced mice of the high, medium and low dosage group of compound preparation of the present invention auricle edema has inhibitory action, and its suppression ratio is all more than 30%.Table 6 is the influence of each group medicine xylol induced mice auricle edema (x ± s).
Table 6
| Group | The example number | The swelling rate | Suppression ratio (%) |
| Dosage group compound preparation low dose group of the present invention in the blank group ibuprofen group compound preparation high dose group of the present invention compound preparation of the present invention | 12 12 12 12 13 | 1.32±0.35 0.75±0.25 * 0.87±0.31 △* 0.89±0.32 △* 0.92±0.32 △* | / 57 45 43 40 |
Annotate: swelling rate=(cause scorching ear and weigh-do not cause scorching ear heavily)/do not cause scorching ear to weigh
*With blank group P＜0.05;
△With ibuprofen group P＞0.05
Rat carrageenan toes swelling method is got 40 of SD rats, and body weight 160g ± 8g is divided into 5 groups at random by body weight, and 8 every group, male and female half and half.Test the same day, the normal control group gives the equivalent normal saline, ibuprofen group 118mg/Kg, compound preparation I group 0.16g/Kg of the present invention, compound preparation II group 0.31g/Kg of the present invention, compound preparation III group 0.62g/Kg of the present invention.Each is organized medicine and irritates stomach, and administration capacity 0.2ml/ only.Chondrus ocellatus Holmes with 1% is a proinflammatory agent, respectively at rat right hind leg foot plantar subcutaneous injection 0.1ml.Cause scorching preceding mensuration and respectively organize the normal volume of the right back sole of the foot of rat, cause scorching afterwards 15min, 1h, 2h, 4h, 6h, 24h and measure the volume of respectively organizing the right back sole of the foot of rat again.The record result is calculated as follows the swelling rate.Swelling rate (%)=[(cause scorching metapedes sole of the foot volume--cause scorching front foot sole of the foot volume)]/causing scorching front foot sole of the foot volume * 100%, the result shows that compound preparation low dose group of the present invention has the effect that suppresses rat paw edema preferably, and keeps effect.
Table 7 causes the influence (x ± s) of rat paw edema for each group medicine on Carrageenan.
Table 7
| Medicine | Cause scorching back different time swelling rate | |||||
| 15min | 1h | 2h | 4h | 6h | 24h | |
| Dosage group compound preparation low dose group of the present invention in the blank group Fenbid group compound preparation high dose group of the present invention compound preparation of the present invention | 0.38± 0.12 0.49± 0.08 △ 0.41± 0.10 △ 0.46± 0.12 △ 0.26± 0.22 △ | 0.63± 0.10 0.48± 0.13 * 0.54± 0.13 △ 0.61± 0.25 △ 0.39± 0.16 * | 0.69± 0.16 0.72± 0.21 △ 0.65± 0.08 △ 0.66± 0.24 △ 0.40± 0.19 * | 0.55± 0.16 0.39± 0.17 △ 0.50± 0.07 △ 0.52± 0.16 △ 0.34± 0.20 * | 0.51± 0.07 0.22± 0.02 * 0.35± 0.07 △ 0.37± 0.22 △ 0.19± 0.06 * | 0.26± 0.08 0.06± 0.01 * 0.02± 0.01 * 0.18± 0.04 △ 0.09± 0.01 * |
Annotate:
*With blank group P＜0.05;
△With blank group P＞0.05
The experiment of test example 2 analgesic activities
Experiment material
1) be subjected to the reagent thing: compound preparation of the present invention is a compound Chinese medicinal preparation.
2) animal subject: Kunming kind white mice, body weight 20g ± 0.5g, male and female half and half, the SD rat is provided by Shanghai Univ. of Traditional Chinese Medicine's Experimental Animal Center.
Experimental technique and result
The mice hot plate method adopts the mice hot plate method, and the control experimental temperature is 18 ℃, and hot plate temperature is 55 ℃ ± 0.5 ℃.Mice is put on the hot plate, to occurring licking sufficient required time, as pain threshold.Get 60 of the threshold of pain qualified (5-30 second) white mice, be divided into 5 groups at random by body weight, 12 every group, male and female half and half.Test the same day, the normal control group gives the equivalent normal saline, ibuprofen group 157mg/Kg, compound preparation I group 0.2g/Kg of the present invention, compound preparation II group 0.4g/Kg of the present invention, compound preparation III group 0.8g/Kg of the present invention.Each is organized medicine and irritates stomach, and administration capacity 0.2ml/ only.0.5 hour, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours mice pain threshold before the mensuration medication, after the medication.The result shows, all the improve effect of the mice threshold of pain of three kinds of dosage groups of compound preparation of the present invention, and very fast (1 hour) appear in peak value, continues to begin after 1 hour to descend.Table 8 is a medicine to the influence of the mice threshold of pain (unit: the s of x ± s).
Table 8
| Group | Before the medication | 0.5 hour | 1 hour | 1.5 hour | 2 hours | 3 hours | 4 hours |
| Dosage group compound preparation low dose group of the present invention in the blank group Fenbid group compound preparation high dose group of the present invention compound preparation of the present invention | 5.90± 1.28 5.06± 1.27 ☆ 5.20± 1.19 ☆ 5.77± 1.43 ☆ 5.50± 0.98 ☆ | 5.38± 1.15 5.88± 1.96 ☆ 8.51± 2.47 **△ 8.52± 1.32 **△ 7.93± 2.48 *△ | 6.00± 1.47 8.09± 2.63 * 10.42± 2.89 ** 9.96± 3.26 **△ 8.80± 2.18 * | 6.57± 1.75 11.21± 4.88 ** 9.51± 2.72 * 8.61± 1.89 * 9.84± 2.29 * | 7.75± 1.41 13.71± 7.05 ** 9.16± 3.10 ☆ 9.05± 3.32 ☆ 7.23± 1.23 ☆ | 8.89± 2.21 12.59± 4.62 ** 8.58± 2.33 ☆ 6.67± 2.33 ☆ 6.59± 1.70 ☆ | 9.74± 2.09 10.12 ±3.79 ☆ 6.37± 1.39 5.49± 1.71 5.67± 1.43 |
Annotate: point is compared with the blank group at the same time,
*P＜0.01,
*P＜0.05,
☆P＞0.05; Point is compared with the ibuprofen group at the same time
△P＜0.05
Mouse writhing method laboratory animal and grouping, each organizes dosage, the same hot plate method of medication natural law, in the last administration after 60 minutes, 0.5% acetum 0.2ml/ of the new preparation of lumbar injection only, the record mice each group occurs in writhing response time and 10 minutes and turns round the body number of times and (with the abdominal part indent, stretch hind leg, buttocks is raised and is standard), calculate the writhing response suppression ratio.Writhing response suppression ratio (%)=[(matched group is on average turned round the body number of times--the administration group is on average turned round the body number of times)/matched group is on average turned round the body number of times] * 100%.The writhing response suppression ratio is no analgesic activity less than 25%, and the writhing response suppression ratio is weak analgesic activity at 25-40%, and the writhing response suppression ratio is the moderate analgesic activity at 40-55%, and the writhing response suppression ratio is strong analgesic activity greater than 55%.The result shows that compound preparation of the present invention has certain analgesic activity, and certain dose-effect relationship is arranged.Table 9 is writhing method analgesic experiment result.
Table 9
| Group | N | Turned round the body number of times in 10 minutes | Analgesia rate (%) |
| Dosage group compound preparation high dose group of the present invention compound preparation low dose group of the present invention in the blank group Fenbid group compound preparation of the present invention | 12 12 12 12 12 | 107±16.2 46.0±1.41 * 74.0±12.7 * 65.0±1.41 * 81.5±14.8 | / 57 31 39 24 |
Annotate: compare with the blank group,
*P＜0.05
Rat writhing method SD rat, male and female half and half, body weight 200g ± 5g with radiant heat irradiation in rats afterbody, is the pain indicator reaction with the whipping, the record response latency is as pain threshold.Detect in advance, with the whipping time the 5-10 rat of second, laboratory animal is divided 5 groups, every group 8, test the same day, the normal control group gives the equivalent normal saline, ibuprofen group 118mg/Kg, compound preparation I group 0.16g/Kg of the present invention, compound preparation II group 0.31g/Kg of the present invention, compound preparation III group 0.62g/Kg of the present invention.Each is organized medicine and irritates stomach, and administration capacity 0.2ml/ only.Follow-on test secondary, its average be as the basic threshold of pain, surveys once to the medication 2 hours continuously thereafter every half an hour.Whipping do not occur 30 seconds if irradiation surpasses in the test, promptly interrupt irradiation.The result shows that compound preparation of the present invention is basic, normal, high all to have the effect in prolong rats pain response time in various degree with ibuprofen.Table 10 is the influence of medicine to the rat threshold of pain.
Table 10
| Group | The pain response time (second) | (%) improved in the threshold of pain | ||||
| Before | 0.5h | 1.0h | 1.5h | 2.0h | ||
| I group II group III group ibuprofen blank | 7.4±1.0 8.1±1.0 6.2±0.7 7.2±1.2 6.9±0.9 | 9.1±1.7 11.4±2.0 10.8±2.1 11.9±2.8 7.1±1.2 | 12.9±3.5 14.7±0.9 13.2±3.1 17.5±4.2 6.6±2.3 | 11.5±2.4 15.3±1.2 15.5±2.8 15.0±5.4 7.0±1.1 | 9.8±1.7 12.4±4.1 16.5±4.0 11.0±3.3 7.2±1.4 | 74.3 89.6 165.9 143.6 / |
Test example 3 compound preparations of the present invention are to the pharmacodynamics test of cartilage degradation protective effect
Compound preparation of the present invention is inquired into the protective effect of medicine to cartilage degradation to two aspects that influence of the black Mus constitutional kneecap arthrosis cartilage pathology tissue morphology meterological of C57 and SOD in serum, NO.
(1) to the research of the black Mus constitutional kneecap arthrosis cartilaginous tissue morphometry of C57
100 of the black Mus of animal: adult healthy C57, the male and female ratio is 2: 1, is provided by Shanghai Univ. of Traditional Chinese Medicine's Experimental Animal Center.Mice is bred in male and female pairing in 2: 1, the generation mice brother-sister mating, and the third generation healthy male mice that the close relative breeds is used for experiment.
Modeling method and by stages: the OA model divide early (I), in (II), (III) three phases in evening, male C57 is black, and Mus is freely taken the photograph water, ingests, respectively at Mus 6W in age, 14W, 22W after 1 all acclimatization trainings, on the motion treadmill, carry out the sports load training with the speed of 5Mmin-1, continuous 5min, every day 1 time, stopped for 1 week after continuous 4 weeks, put to death observation respectively at Mus 12W in age, 20W, 28W.Table 11 be mice knee joint OA by stages with method.
Table 11
| By stages | The load time started | Load interval | The medicine feed time started | The medicine feed interval | Point of observation |
| (II) late period in (I) mid-term (III) in early days | 6W 14W in age 22W in age age | 4W 4W 4W | 8W 16W in age 24W in age age | 4W 4W 4W | 12W 20W in age 28W in age age |
Organize the meterological method: according to concerning with meniscal position, tibial side loading portion articular cartilage is divided into 5 district's bands, I: meniscus prosthomere lining portion, near II: the meniscus prosthomere free edge, III: between saving before and after the meniscus, IV: near the meniscus deutomerite free edge, V: meniscus deutomerite lining portion.Be put under the eyepiece chondrocyte density in non-calcification layer thickness of articular cartilage of measuring each district's band, the unit are with C5, C6 micrometer, and calculate its average.With reference to Mankin Score method, calculate cartilage degradation degree (OA integration).
The result shows, Mus 12W in age, and the model group cartilage thickness descends, but compares no significant difference still with blank group and each treatment group.Mus 20W in age, the cartilage thickness model group is starkly lower than blank group, and compound preparation group of the present invention has decline, but is higher than model group and ibuprofen group, and significant difference is arranged.Ibuprofen group and model group no significant difference.Chondrocyte density increases the weight of and descends gradually with the OA severity after of short duration increasing.In morning, mid-term, the chondrocyte density of compound preparation group of the present invention is higher than model group and ibuprofen group, and this species diversity shows the most obvious when 18W, and this phase compound preparation group of the present invention chondrocyte density still is higher than the glucosamine group.28W, between each treated animal chondrocyte density and cartilage thickness the variation bigger, the cartilage that has strips off seriously, the instrumentation difficulty.OA integration obvious difference between each group.Early, middle and late three phases, the cartilaginous tissue regression of compound preparation group of the present invention all is lower than model group, and shows the reaction of repair of cartilage such as the loose and collection of chondrocyte significantly bunch.
Table 12 is the OA integration evaluation of cartilage degeneration.Table 13 is the comparison (n=8) of mice articular cartilage thickness.Table 14 is the comparison (n=8) of articular chondrocytes density.Table 15 is the influence of medicine to black mouse model OA integration.
Table 12
| Degree | Integration |
| Irregular cartilage top layer, normal cartilage top layer is irregular, the tide line disorderly or on move crack to the cartilage layer of dividing a word with a hyphen at the end of a line, or cartilage surface ulceration crack is to the cartilage emitting layer, or ulceration crack, many places, cartilage top layer is to the cartilaginous calcification layer, cartilage strips off seriously, and the damaged whole cartilage layers of the unclear whole cartilage layers of cartilage structure is damaged and expose bone structure | 0 1 2 3 4 8 12 16 |
Table 13
| Group | Cartilage thickness | ||
| I | II | III | |
| Blank group model group compound preparation group of the present invention ibuprofen group glucosamine group | 81.39±3.30 74.49±12.09 80.55±4.63 76.15±7.27 76.16±6.21 | 80.71±2.93 ★ 37.50±11.09 ▲ 69.76±5.85 ★* 39.78±9.57 ▲ 51.21±4.95 ★ | 78.64±5.67 / / / / |
Annotate: the q check,
★Compare P＜0.05 with model group; The t check,
▲With the I phase is compared P＜0.05 on the same group;
*Compare P＜0.05 with the ibuprofen group.
Table 14
| Group | Chondrocyte density (cs/mm 3) | ||
| I | II | III | |
| Blank group model group compound preparation group of the present invention ibuprofen group glucosamine group | 3.79±0.22 ★ 2.95±1.57 4.04±0.16 ★*☆ 3.18±0.85 3.26±0.72 ★ | 3.99±0.41 1.88±1.37 ▲ 3.77±0.21 ★* 2.35±1.09 3.06±0.95 ★ | 3.26±0.85 / / / / |
Annotate: the q check,
★Compare P＜0.05 with model group;
▲With the I phase is compared P＜0.05 on the same group;
*Compare P＜0.05 with the ibuprofen group;
☆Compare P＜0.05 with the glucosamine group.
Table 15
| Group | The OA integration | ||
| I | II | III | |
| Blank group model group compound preparation group of the present invention ibuprofen group glucosamine group | 0 ★ 3.50±2.98 1.00±1.07 ★ 1.25±1.04 ★ 1.50±1.41 ★ | 0.25±0.71 ★* 5.37±2.97 ▲ 2.00±1.51 ★* 4.50±2.33 ▲ 3.75±1.98 | 2.25±2.71 ★ 8.00±4.62 ◆ 3.43±2.33 ★ 7.00±4.34 ◆ 4.73±2.51 |
Annotate: the q check,
★Compare P＜0.05 with model group; The t check,
▲With the I phase is compared P＜0.05 on the same group;
*Compare P＜0.05 with the ibuprofen group;
◆With the II phase is compared P＜0.05 on the same group.
(2) to the influence of the black Mus constitutional kneecap arthrosis SOD in serum of C57, NO, HA
Animal: C57 deceives Mus.
Modeling method reaches by stages with above-mentioned (1).
Grouping and observation medicine: early, middle and late three phases are respectively established 4 observation groups: compound preparation group of the present invention, ibuprofen group, model control group and blank group, 10 of every treated animals.Proportionately the body surface area calculates dosage, gastric infusion, and every day 1 time, compound preparation of the present invention and ibuprofen and glucosamine dosage are respectively 0.35,0.16,0.13gkg-1d-1.Continuous 4 weeks of medicine feed.Model group and blank group are fed into the equivalent distilled water.
Observation index and method
The mensuration oxidoreduction enzyme process of superoxide dismutase (SOD), medicine box provides (lot number 970911) by the poly-Lik-Sang thing Institute for Medical Research in Nanjing.
The mensuration nitrate reductase method of NO, medicine box provides (lot number 980211) by the poly-Lik-Sang thing Institute for Medical Research in Nanjing.
The mensuration radio immunoassay of HA, medicine box provides (lot number 971201) by INM.
The result shows, among the black Mus OA, late period model group SOD with blank group zero difference, compound preparation group of the present invention is apparently higher than blank group and ibuprofen and glucosamine group.OA mid-term, the model group serum NO levels is organized apparently higher than blank; In late period, NO organizes but still be higher than blank than slightly descending mid-term.Compound preparation group of the present invention is starkly lower than model group and ibuprofen and glucosamine group.OA mid-term, model group serum HA content is organized apparently higher than blank, and compound preparation group of the present invention is starkly lower than model group and glucosamine, ibuprofen group; In late period, HA organizes but still be higher than blank than slightly descending mid-term, no significant difference between each group.The result confirms that compound preparation of the present invention plays a protective role to cartilage degradation, can delay cartilage degeneration.Table 16 is the influence of medicine to the black Mus SOD in serum of C57.Table 17 is the influence of medicine to the black Mus serum NO level of C57.Table 18 is the influence of medicine to the black Mus serum HA of C57.
Table 16
| Group | SOD(NU/mm) | |||
| n | II | n | III | |
| Blank group model group compound preparation group of the present invention ibuprofen group glucosamine group | 8 7 8 7 7 | 112.81±16.99 112.74±14.22 156.06±11.52 ★* 114.16±16.97 128.34±19.24 | 8 7 7 6 7 | 110.64±13.99 102.99±15.32 129.55±13.10 ★* 95.94±8.84 114.43±13.88 |
Annotate: the q check,
★Compare P＜0.05 with model group;
*Compare P＜0.05 with ibuprofen, glucosamine group.
Table 17
| Group | NO(umol/L) | |||
| n | II | n | III | |
| Blank group model group compound preparation group of the present invention ibuprofen group glucosamine group | 8 7 8 7 7 | 31.46±6.72 ★ 74.06±18.02 48.79±16.89 ★ 53.40±16.34 * 77.69±18.92 * | 8 7 7 6 7 | 31.62±6.70 ★ 67.25±11.80 42.19±14.68 ★ 53.40±16.34 * 66.92±20.60 * |
Annotate: the q check,
★Compare P＜0.05 with model group;
*Compare P＜0.05 with ibuprofen, glucosamine group.
Table 18
| Group | HA(umol/l) | |||
| n | II | n | III | |
| Blank group model group compound preparation group of the present invention ibuprofen group glucosamine group | 8 7 8 7 7 | 117.36±33.77 ★ 191.78±39.97 128.36±35.20 ★* 157.34±46.69 166.03.±40.33 | 8 7 7 6 7 | 113.11±14.55 ★ 142.20±60.08 138.10±27.40 166.24±61.09 158.59±35.41 |
Annotate: the q check,
★Compare P＜0.05 with model group;
*Compare P＜0.05 with ibuprofen, glucosamine group.
The experiment and the clinical research of cumulated volume invention compound preparation, the result shows to have following advantage:
(1) the antiinflammatory experimental result shows that high, medium and low dosage all has certain antiinflammatory, analgesic activity.
(2) to the observation of cartilage pathology tectology, confirm that it can improve chondrocyte density and thickness, thereby reduce the osteoarthritis integration, delay cartilage degeneration.
(3) experiment confirm compound preparation of the present invention can promote the black Mus SOD in serum content reduction of C57 constitutional OA NO, HA content, cartilage degradation is played a protective role, thereby can be used for the treatment of cartilage degeneration class disease.
The experimental result of compound preparation of the present invention shows, can better treat osteoarthritis, and taking convenience is taken without any side effects for a long time.Preparation method disclosed by the invention can keep the effective ingredient in the medical material expeditiously, simplifies the preparation technology of Chinese medicine preparation, helps big operation of producing.
Further set forth preparation method of the present invention by the following examples.
Embodiment 1
Take by weighing by each medical material proportioning: the Radix Paeoniae Alba 30%; Radix Gentianae Macrophyllae 15%; Concha Ostreae 30%; Radix Glycyrrhizae 15%; Scolopendra 5%; Scorpio 5%, the Radix Paeoniae Alba, Radix Gentianae Macrophyllae, Concha Ostreae and Radix Glycyrrhizae, 90 ℃ of extracting in water secondaries, add for the first time 6 times of amounts of water, extracted 30 minutes, and added 4 times of amounts of water for the second time, extracted 30 minutes, filter, merge fried liquid, being evaporated to relative density is 1.20～1.25 (80 ℃) extractum, (60 ℃ of drying under reduced pressure, 0.08MPa), be ground into fine powder (crossing 40 orders); Other gets Scolopendra and Scorpio, pulverizes 40 orders,
60Co-gamma-ray irradiation sterilization (8KGy) with the dry extract mixing, incapsulates promptly and gets (0.35g/ grain).
Embodiment 2
Take by weighing by each medical material proportioning: the Radix Paeoniae Alba 40%; Radix Gentianae Macrophyllae 10%; Concha Ostreae 30%; Radix Glycyrrhizae 10%; Scolopendra 5%; Scorpio 5%, the Radix Paeoniae Alba, Radix Gentianae Macrophyllae, Concha Ostreae and Radix Glycyrrhizae, 90 ℃ of extracting in water secondaries, the inferior for the first time 6 times of amounts of water that add, extracted 30 minutes, and added 4 times of amounts of water for the second time, extracted 30 minutes, filter, merge fried liquid, being evaporated to relative density is 1.20～1.25 (80 ℃) extractum, (60 ℃ of drying under reduced pressure, 0.08MPa), be ground into fine powder (crossing 40 orders); Other gets Scolopendra and Scorpio, pulverizes 40 orders,
60Co-gamma-ray irradiation sterilization (8KGy) with the dry extract mixing, incapsulates promptly and gets (0.35g/ grain).
Embodiment 3
Take by weighing by each medical material proportioning: the Radix Paeoniae Alba 20%; Radix Gentianae Macrophyllae 20%; Concha Ostreae 40%; Radix Glycyrrhizae 18%; Scolopendra 1%; Scorpio 1%; , the Radix Paeoniae Alba, Radix Gentianae Macrophyllae, Concha Ostreae and Radix Glycyrrhizae, 90 ℃ of extracting in water secondaries, the inferior for the first time 6 times of amounts of water that add, extracted 30 minutes, and added 4 times of amounts of water for the second time, extracted 30 minutes, filter, merge fried liquid, being evaporated to relative density is 1.20～1.25 (80 ℃) extractum, (60 ℃ of drying under reduced pressure, 0.08MPa), be ground into fine powder (crossing 40 orders); Other gets Scolopendra and Scorpio, pulverizes 40 orders,
60Co-gamma-ray irradiation sterilization (8KGy) with the dry extract mixing, incapsulates promptly and gets (0.35g/ grain).
Claims (6)
1. a compound Chinese medicinal preparation for the treatment of osteoarthritis is characterized in that with the Chinese crude drug Radix Paeoniae Alba, Radix Gentianae Macrophyllae, Concha Ostreae, Radix Glycyrrhizae, Scolopendra and Scorpio be principal agent, be equipped with adjuvant and make capsule preparations, and the mass percent of described each medical material consumption such as following,
Radix Paeoniae Alba 20-40%, Radix Gentianae Macrophyllae 10-20%, Concha Ostreae 20-40%, Radix Glycyrrhizae 10-20%, Scolopendra 1-5%, Scorpio 1-5%.
2. by the compound Chinese medicinal preparation of the described treatment osteoarthritis of claim 1, wherein the mass percent of each medical material consumption is:
Radix Paeoniae Alba 30-40%, Radix Gentianae Macrophyllae 15-20%, Concha Ostreae 30-35%, Radix Glycyrrhizae 15-20%, Scolopendra 1-5%, Scorpio 1-5%.
3. by the compound Chinese medicinal preparation of the described treatment osteoarthritis of claim 1, wherein the mass percent of each medical material consumption is: the Radix Paeoniae Alba 30%, Radix Gentianae Macrophyllae 15%, Concha Ostreae 30%, Radix Glycyrrhizae 15%, Scolopendra 5%, Scorpio 5%.
4. press the preparation method of the compound Chinese medicinal preparation of the described treatment osteoarthritis of claim 1, it is characterized in that by following step: take by weighing by each medical material proportioning: the Radix Paeoniae Alba, Radix Gentianae Macrophyllae, Concha Ostreae, Radix Glycyrrhizae, Scolopendra, Scorpio, with the Radix Paeoniae Alba, Radix Gentianae Macrophyllae, Concha Ostreae and Radix Glycyrrhizae, 90 ℃ of extracting in water secondaries, for the first time add 6 times of amounts of water, extracted 30 minutes, add 4 times of amounts of water for the second time, extracted 30 minutes, and filtered, merge fried liquid, being evaporated to relative density is 1.20～1.25 extractum, 80 ℃; Drying under reduced pressure, 60 ℃, 0.08MPa is ground into fine powder and crosses 40 orders; Other gets Scolopendra and Scorpio, pulverizes 40 orders, the sterilization of 60Co-gamma-ray irradiation, and 8KGy, incapsulates the 0.35g/ grain with the dry extract mixing.
5. press the preparation method of the compound Chinese medicinal preparation of the described treatment osteoarthritis of claim 4, the consumption proportion that it is characterized in that each medical material is: the Radix Paeoniae Alba 30%, Radix Gentianae Macrophyllae 15%, Concha Ostreae 30%, Radix Glycyrrhizae 15%, Scolopendra 5%, Scorpio 5%, wherein the Radix Paeoniae Alba, Radix Gentianae Macrophyllae, Concha Ostreae and Radix Glycyrrhizae decocting are 2 times, after the concentrating under reduced pressure drying, are ground into fine powder; Wherein Scolopendra and Scorpio are directly pulverized, and incapsulate behind the mixing.
6. press the preparation method of the compound Chinese medicinal preparation of the described treatment osteoarthritis of claim 4, the extraction conditions of the wherein said medical material Radix Paeoniae Alba, Radix Gentianae Macrophyllae, Concha Ostreae and Radix Glycyrrhizae is: amount of water is 6 times for the first time, amount of water is 4 times for the second time, extracting temperature is 90 ℃, extraction time is 30min, and extraction time is 2 times.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100246572A CN1301728C (en) | 2005-03-25 | 2005-03-25 | Chinese medicine compound preparation for treating osteoarthropathy and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100246572A CN1301728C (en) | 2005-03-25 | 2005-03-25 | Chinese medicine compound preparation for treating osteoarthropathy and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1686253A CN1686253A (en) | 2005-10-26 |
| CN1301728C true CN1301728C (en) | 2007-02-28 |
Family
ID=35304295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100246572A Active CN1301728C (en) | 2005-03-25 | 2005-03-25 | Chinese medicine compound preparation for treating osteoarthropathy and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1301728C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109568399A (en) * | 2017-09-28 | 2019-04-05 | 同溢堂药业有限公司 | A kind of Chinese prescription preparation for treating rheumatoid arthritis |
-
2005
- 2005-03-25 CN CNB2005100246572A patent/CN1301728C/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN1686253A (en) | 2005-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1814167A (en) | Health-care for diabetes | |
| CN1457808A (en) | Iron scale dendrobium compound preposition and preparation and use | |
| CN102366595A (en) | Medicine for treating diabetes and preparation method thereof | |
| CN1907316A (en) | Orthopaedics disease treating and preventing medicinal composition | |
| CN1879766A (en) | Medicine for treating rheumatism and preparation method thereof | |
| CN103463407B (en) | Reason machine Jiangtang capsule | |
| CN1742775A (en) | Medicine composition for preventing and treating orthopedic diseases | |
| CN1301728C (en) | Chinese medicine compound preparation for treating osteoarthropathy and its preparation method | |
| CN101049360A (en) | Preparation of Chinese traditional medicine for treating gout disease, and application of extractive of Chinese feveruine | |
| CN1067555C (en) | Application of medicinal combination containing termite population and main nest bacterial nursery | |
| CN1197614C (en) | Chinese medicine cap sule for treating prostatic disorders | |
| CN1824204A (en) | Medicinal composition for treating acute urarthritis and its preparation method | |
| CN100335090C (en) | Medicinal composition for tonifying kidney and eliminating obstruction, and its preparing method | |
| CN1054762C (en) | Medicine for treatment of epilepsy | |
| CN102335362B (en) | Traditional Chinese medicine for treating insulin resistance of type 2 diabetes | |
| CN101062314A (en) | Medicine for curing gout and its preparing method | |
| CN1686302A (en) | Traditional Chinese medicine for treating non-alcoholic simple fatty liver and its preparation method | |
| CN115518133B (en) | Traditional Chinese veterinary medicine composition for treating cat stranguria | |
| CN1186052C (en) | Medicine for treatment of pelvic inflammation, its preparation and preparing method | |
| CN1282471C (en) | Medicine for treating anaphylactic dermatosis | |
| CN106421523A (en) | Traditional Chinese medicine compound for treating gout | |
| CN1899436A (en) | Method for preparing Chinese medicine compound preparation and use | |
| CN105194352A (en) | Traditional Chinese medicine composition capable of improving learning and memory abilities and preparation method thereof | |
| CN1201742C (en) | Hypoglycemic health-care food for diabetes type II; | |
| CN1181874C (en) | Medicine for acute cerebral hemorrhage and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHANGHAI FOSUN PHARMACEUTICAL INDUSTRIAL DEVELOPME Free format text: FORMER OWNER: SHUGUANG HOSPITAL AFFILIATED TO SHANGHAI UNIVERSITY OF CHINESE MEDICINE Effective date: 20141106 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 200021 HUANGPU, SHANGHAI TO: 200010 PUDONG NEW AREA, SHANGHAI |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20141106 Address after: 200010, room 25, 350 Zhenkang Road, Cambridge, Shanghai, Pudong New Area Patentee after: Shanghai FOSUN Pharmaceutical Co.,Ltd. Address before: 200021 Shanghai city Pu Road No. 185 Patentee before: Shuguang Hospital Affiliated to Shanghai University of Chinese Medicine |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210414 Address after: 221000 south side of Dongshan, Jinshanqiao Development Zone, Xuzhou City, Jiangsu Province Patentee after: JIANGSU WANBANG BIOPHARMACEUTICAL GROUP Co.,Ltd. Address before: Room 350, 25 kangtu Road, Kangqiao Town, Pudong New Area, Shanghai 200010 Patentee before: SHANGHAI FOSUN PHARMACEUTICAL DEVELOPMENT Co.,Ltd. |